[NH2:1][C:2]1[CH:7]=[C:6]([O:8][C:9]2[C:14]([F:15])=[CH:13][C:12]([NH:16][C:17]([C:19]3[C:20](=[O:32])[N:21]([C:26]4[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=4)[N:22]([CH3:25])[C:23]=3[CH3:24])=[O:18])=[C:11]([Cl:33])[CH:10]=2)[CH:5]=[CH:4][N:3]=1.CCN(CC)CC.Cl[C:42](OC1C=CC=CC=1)=[O:43].[NH:51]1[CH2:56][CH2:55][O:54][CH2:53][CH2:52]1>C1COCC1>[Cl:33][C:11]1[C:12]([NH:16][C:17]([C:19]2[C:20](=[O:32])[N:21]([C:26]3[CH:27]=[CH:28][CH:29]=[CH:30][CH:31]=3)[N:22]([CH3:25])[C:23]=2[CH3:24])=[O:18])=[CH:13][C:14]([F:15])=[C:9]([CH:10]=1)[O:8][C:6]1[CH:5]=[CH:4][N:3]=[C:2]([NH:1][C:42]([N:51]2[CH2:56][CH2:55][O:54][CH2:53][CH2:52]2)=[O:43])[CH:7]=1To a suspension of N-(4-((2-aminopyridin-4-yl)oxy)-2-chloro-5-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (234 mg, 0.5 mmol) and Et3N (0.1 mg, 1 mmol) in THF (5 mL) was added phenyl chloroformate (0.16 mg, 1 mmol). The mixture was stirred at rt for 2 hours, then morpholine (0.44 mL, 5 mmol) was added. The reaction mixture was stirred rt for 24 hours, then partitioned between aq NH4Cl (30 mL) and DCM (30 mL). The organic phase was separated and the aqueous phase extracted with DCM (30 mL×3). The combined organic phases were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/CH3OH (v/v)=50/1) to give the title compound as a white solid (145 mg, 49.9%).
Loading…